Seelos Therapeutics will begin animal studies to test a gene therapy approach to deliver its investigational candidate SLS-007 for…
Articles by Patricia Inácio, PhD
The U.S. Food and Drug Administration (FDA) has expanded Abbott’s Infinity Deep Brain Stimulation (DBS) system approval to…
Secondary parkinsonism can be caused by a cavernoma — a cluster of abnormal blood vessels — located in a brain…
Biogen is adding Pfizer’s PF-05251749 — a regulator of the body’s inner clock — to its group of potential…
Cannabinoid-based formulations in development at GB Sciences were able to ease behavioral symptoms linked to the loss of dopamine…
Patient treatment has been completed in a Phase 1/2 clinical trial testing cerebral dopamine neurotrophic factor (CDNF) for…
Gosuranemab failed to meet its primary and key secondary goals in a Phase 2 study evaluating its use in treating …
A new method allows researchers to develop adeno-associated virus (AVV) — commonly used as the vehicle for gene therapies —…
Clumps, or aggregates of alpha-synuclein protein in the brain, a hallmark of Parkinon’s disease, are more heterogeneous than…
Mission Therapeutics and AbbVie have identified several molecules, called deubiquitylating enzymes, or DUBs, that may be potential therapeutic…